ABC.L Regulatory News (ABC)

ABCAM PLC

("Abcam" or "the Company")

AGM Statement

Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, is holding its Annual General Meeting this morning. Michael Redmond, Abcam's Chairman, will make the following statement at the meeting:

"I am pleased to report that the 2011 financial year has started well and the Company has traded in line with our expectations for the first four months of the year. Demand for our products continues to be strong and we have had some benefit from the weakness of sterling over the comparative period last year. Whilst we have seen little impact to date, governments, especially those in the West, are still under pressure to address their deficits and we remain mindful that this may at some point have an impact on our business should it result in reduced research funding."

For further information please contact:

Notes for editors:

About Abcam plc

Abcam is a producer and distributor of research-grade antibodies and related products, headquartered in Cambridge, United Kingdom, with US offices in Cambridge, Massachusetts, and San Francisco, California, and Far East offices in Tokyo and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party products to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All products are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 66,000 products, most of which are antibodies, from over 250 suppliers and employs 270 staff.